Development of 177Lu‐nanobodies for radioimmunotherapy of HER2‐positive breast cancer: evaluation of different bifunctional chelators
- 20 March 2012
- journal article
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 7 (2) , 254-264
Abstract
Nanobodies show favourable pharmacokinetic characteristics for tumor targeting, including high tumor‐to‐background‐ratios. Labelled with a therapeutic radionuclide, nanobodies could be used as an adjuvant treatment option for HER2‐overexpressing minimal residual disease. The therapeutic radionuclide Lutetium‐177 is linked to the nanobody using a bifunctional chelator. The choice of the bifunctional chelator could affect the in vivo behaviour of the radiolabeled nanobody. Consequently, we compared four different bifunctional chelators ‐ p‐SCN‐Bn‐DOTA, DOTA‐NHS‐ester, CHX‐A”‐DTPA or 1B4M‐DTPA ‐ in order to select the optimal chemical link between Lutetium‐177 and a HER2 targeting nanobody.MS results revealed different degrees of chelator‐conjugation. High stability in time was observed, together with nanomolar affinities on HER2‐expressing tumor cells. Ex vivo biodistributions as well as SPECT/micro‐CT analyses showed high activities in tumors expressing medium HER2 levels with low background activity except for the kidneys. The 1B4M‐DTPA‐coupled conjugate was further evaluated in a high HER2‐expressing tumor model. Here, tumor uptake values of 5.99 ± 0.63, 5.12 ± 0.17, 2.83 ± 0.36 and 2.47 ± 0.38 %IA/g were obtained at 1, 3, 24 and 48h p.i., which coincided with exceptionally low background values, except for the kidneys, and unprecedented tumor‐to‐background ratios. No specific binding was observed in a HER2‐negative model.In conclusion, the in‐house developed anti‐HER2 nanobody 2Rs15dHIS can be successfully labeled with 177Lu using different bifunctional chelators. Both macrocyclic and acyclic chelators show high stability in time. High specific tumor uptake combined with the lowest background uptake was measured using the 1B4M‐DTPA‐based conjugate. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
This publication has 22 references indexed in Scilit:
- Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging PropertiesJournal of Nuclear Medicine, 2011
- Localization, mechanism and reduction of renal retention of technetium‐99m labeled epidermal growth factor receptor‐specific nanobody in miceContrast Media & Molecular Imaging, 2010
- Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligandsNuclear Medicine and Biology, 2010
- Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- HER2+ Breast CancerAmerican Journal of Clinical Pathology, 2008
- Properties, production, and applications of camelid single-domain antibody fragmentsApplied Microbiology and Biotechnology, 2007
- Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligandsNuclear Medicine and Biology, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Current and Potential Therapeutic Uses of Lanthanide RadioisotopesCancer Biotherapy and Radiopharmaceuticals, 2000